AU3820700A - Combined method of treatment comprising an aromatase inhibitor and a further biologically active compound - Google Patents

Combined method of treatment comprising an aromatase inhibitor and a further biologically active compound

Info

Publication number
AU3820700A
AU3820700A AU38207/00A AU3820700A AU3820700A AU 3820700 A AU3820700 A AU 3820700A AU 38207/00 A AU38207/00 A AU 38207/00A AU 3820700 A AU3820700 A AU 3820700A AU 3820700 A AU3820700 A AU 3820700A
Authority
AU
Australia
Prior art keywords
treatment
active compound
biologically active
aromatase inhibitor
combined method
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU38207/00A
Inventor
Enrico Di Salle
Michele Tedeschi
Tiziana Zaccheo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Original Assignee
Pharmacia and Upjohn SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn SpA filed Critical Pharmacia and Upjohn SpA
Publication of AU3820700A publication Critical patent/AU3820700A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU38207/00A 1999-05-18 2000-04-14 Combined method of treatment comprising an aromatase inhibitor and a further biologically active compound Abandoned AU3820700A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9911582.6A GB9911582D0 (en) 1999-05-18 1999-05-18 Combined method of treatment comprising an aromatase inhibitor and a further biologically active compound
GB9911582 1999-05-18
PCT/EP2000/003407 WO2000069467A1 (en) 1999-05-18 2000-04-14 Combined method of treatment comprising an aromatase inhibitor and a further biologically active compound

Publications (1)

Publication Number Publication Date
AU3820700A true AU3820700A (en) 2000-12-05

Family

ID=10853700

Family Applications (1)

Application Number Title Priority Date Filing Date
AU38207/00A Abandoned AU3820700A (en) 1999-05-18 2000-04-14 Combined method of treatment comprising an aromatase inhibitor and a further biologically active compound

Country Status (6)

Country Link
EP (1) EP1178831A1 (en)
JP (1) JP2003512301A (en)
AR (1) AR029451A1 (en)
AU (1) AU3820700A (en)
GB (1) GB9911582D0 (en)
WO (1) WO2000069467A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001289865B2 (en) * 2000-09-08 2007-03-01 Pharmacia Italia S.P.A. Exemestane as chemopreventing agent

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2428249A1 (en) * 2000-11-16 2002-05-23 Pharmacia & Upjohn Company Combination therapy for estrogen-dependent disorders
EP2269603B1 (en) * 2001-02-19 2015-05-20 Novartis AG Treatment of breast tumors with a rapamycin derivative in combination with exemestane
PL392652A1 (en) * 2001-05-16 2010-12-06 Novartis Ag A combination consisting of N-{5-[4-(4-methyl-piperazine-methyl)-benzoiloamido]-2-methylphenyl} -4-(3-pyridyl)-2-pyrimidine-amine and the chemotherapeutic agent, the use thereof, pharmaceutical composition containing thereof a kit containing such a combination
US20090215731A1 (en) 2005-10-19 2009-08-27 Chavah Pty Ltd. Reduction of Side Effects From Aromatase Inhibitors Used for Treating Breast Cancer
JP6091431B2 (en) * 2011-01-31 2017-03-15 ルコラス−エム．ディー．リミテッド Medicinal use
ES2953915T3 (en) 2014-10-22 2023-11-17 Havah Therapeutics Pty Ltd Methods to reduce mammographic breast density and/or breast cancer risk
CN108472302A (en) 2015-10-22 2018-08-31 哈瓦赫治疗有限公司 The method for reducing mammogram breast density and/or mammary cancer risk
WO2020243777A1 (en) 2019-06-03 2020-12-10 Havah Therapeutics Pty Ltd Pharmaceutical formulations and systems for delivery of an androgenic agent and an aromatase inhibitor and methods for use

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001289865B2 (en) * 2000-09-08 2007-03-01 Pharmacia Italia S.P.A. Exemestane as chemopreventing agent

Also Published As

Publication number Publication date
AR029451A1 (en) 2003-07-02
WO2000069467A1 (en) 2000-11-23
GB9911582D0 (en) 1999-07-21
EP1178831A1 (en) 2002-02-13
JP2003512301A (en) 2003-04-02

Similar Documents

Publication Publication Date Title
AU4996300A (en) Method of electroporation-enhanced delivery of active agents
AU4904601A (en) Stent and stent delivery assembly and method of use
AU2466099A (en) Pharmaceutically active compounds and methods of use thereof
AU2337799A (en) Method and compositions for promotion of wound healing
AU4717301A (en) Catheter assembly and method of use
AU1193301A (en) Controlled-power defibrillator and method of defibrillation
AU3929600A (en) Matrix metalloproteinase inhibitors and method of using same
AU3820700A (en) Combined method of treatment comprising an aromatase inhibitor and a further biologically active compound
AU5615500A (en) Method of and devices for telecommunication
AUPQ582400A0 (en) A method of treatment and agents for use therein
AU2002362181A1 (en) Arrangement and method for treatment of a pumpable substance
AUPQ199999A0 (en) A method of treatment and agents useful for same
AU4598400A (en) Method of treatment
AU781936C (en) A method of treatment and agents useful for same
ZA966915B (en) Active compound combinations of pyrethriods and insect development inhibitors.
AUPQ124899A0 (en) A method of treatment and agents useful for same
AUPP865899A0 (en) A method of treatment and agents useful for same
AUPQ065299A0 (en) A method of prophylaxis and treatment and agents useful for same
AUPQ656500A0 (en) A method of treatment and agents for same
AU2499900A (en) Attachable freshener and method of using same
AU3611200A (en) An orthopedic bandage and method of making same
AUPQ645500A0 (en) A method of treatment and agents useful for same
AUPQ800300A0 (en) A method of treatment and agents useful for same
AUPQ021999A0 (en) A method of prophylaxis and treatment and agents useful therefor
AU4385200A (en) A method of prophylaxis and treatment and agents useful therefor

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase